Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891944 | 0.80 | CNR2 (0.56) | CNR2LPAR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9891951 | 0.78 | CNR2 (0.60) | CNR2P2RX7NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9108690 | 0.72 | MAPT (0.63) | CNR2P2RX7NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9893083 | 0.72 | NPC1 (0.47) | CNR2LPAR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9892139 | 0.71 | CNR2 (0.86) | CNR2LPAR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16254959 | 0.71 | NPC1 (0.49) | CNR2LPAR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11706151 | 0.71 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL9891940 | 0.71 | CNR2 (0.58) | CNR2RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL9892389 | 0.71 | CNR2 (0.48) | CNR2P2RX7CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL16542489 | 0.70 | P2RX7 (0.49) | CNR2P2RX7CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010077836-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885P2RX7 26/4885LPAR2 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.